Analysts Set Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Target Price at $56.89

Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) has been assigned a consensus recommendation of “Buy” from the nine research firms that are covering the firm, Marketbeat reports. Nine research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have issued ratings on the stock in […]

Related Keywords

United States ,Canada ,America ,Gary Patou ,Royal Bank ,News Ratings For Xenon Pharmaceuticals Daily ,Polar Capital Holdings Plc ,Jpmorgan Chase Co ,Xenon Pharmaceuticals Inc ,Driehaus Capital Management ,Analyst Recommendations For Xenon Pharmaceuticals ,Xenon Pharmaceuticals ,Institutional Investors Weigh In On Xenon Pharmaceuticals ,Xenon Pharmaceuticals Stock Down ,Insider Transactions At Xenon Pharmaceuticals ,Citigroup ,Nasdaq ,Get Free Report ,Pharmaceuticals Stock Down ,Director Gary Patou ,Capital Management ,Capital Holdings Plc ,Get Free ,Pharmaceuticals Inc ,Xenon Pharmaceuticals Daily ,Nasdaq Xene ,Exene ,Medical ,Ratings ,Consensus ,